Dozens of medications reduce appetite, some by design and others as an unwanted side effect. The list spans stimulants prescribed for ADHD, newer GLP-1 receptor agonists marketed for weight loss, the old diabetes standby metformin, certain antidepressants, chemotherapy drugs, and even nicotine. Each works through a different brain or gut pathway, which means the experience of “not feeling hungry” can vary widely depending on the drug. Understanding which medications blunt appetite and why they do it can help you anticipate changes in eating when starting a new prescription or recognize when appetite loss is a signal worth discussing with your doctor.
Stimulants
Stimulant medications are probably the most familiar appetite suppressants. Drugs like amphetamine, dextroamphetamine, and methylphenidate, commonly prescribed for ADHD, reliably reduce hunger. They boost dopamine and norepinephrine signaling in the brain, which both sharpens focus and dampens the drive to eat. The appetite-suppressing effect is strong enough that reduced food intake and weight loss are among the most frequently reported side effects in children and adults taking ADHD stimulants.
This same mechanism is why stimulant-based drugs have a long history in obesity treatment. Phentermine, either alone or combined with topiramate, is one of the few stimulant-related medications currently approved by the FDA for weight management. Bupropion, an antidepressant with stimulant-like properties, is approved for obesity in combination with the opioid blocker naltrexone. Both phentermine and bupropion address reward-related eating, the kind driven by craving and pleasure rather than genuine caloric need, while also directly suppressing appetite signals.1PubMed Central. Stimulants for the Control of Hedonic Appetite
The practical catch with stimulants is that appetite tends to return when the drug wears off. Many people on ADHD medication notice they eat very little during the day and then overeat in the evening once the dose fades. If you are prescribed a stimulant and find yourself skipping meals, it is worth planning calorie-dense snacks or meals for when you do feel hungry rather than letting the whole day go by without eating.
GLP-1 Receptor Agonists
The drugs getting the most attention right now for appetite suppression are GLP-1 receptor agonists, including semaglutide (sold as Ozempic and Wegovy) and liraglutide (Saxenda). These medications mimic a gut hormone called GLP-1 that your body normally releases after eating. Their effect on hunger is dramatic: many people describe food simply becoming less interesting, with cravings and the urge to snack fading substantially.
A common assumption is that GLP-1 drugs work mainly by slowing down how quickly food leaves your stomach, making you feel full longer. Research tells a more nuanced story. A study examining liraglutide found that delayed gastric emptying accounted for only about four to six percent of the variation in appetite measures among participants. No consistent relationship between stomach emptying speed and appetite reduction appeared in the liraglutide group alone.2Wiley Online Library. Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying The bigger action appears to happen in the brain, where GLP-1 receptors in areas that regulate hunger and reward directly dial down appetite signals.
One important consideration with GLP-1 drugs is what happens when you stop them. The weight loss they produce is accompanied by metabolic adaptations: your body lowers its energy expenditure and ramps up appetite-promoting hormones, which can drive significant weight regain once therapy ends.3PubMed Central. Beyond GLP-1 Agonists: An Adaptive Ketogenic–Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management This rebound effect is a major reason many clinicians view these medications as long-term commitments rather than short courses.
Metformin
Metformin has been a first-line diabetes drug for decades, and many people who take it notice they eat less without really trying. For a long time, no one could explain why. Recent research has pinpointed the mechanism: metformin triggers the body to produce more of a signaling molecule called GDF15. This peptide acts on a receptor in the brainstem, specifically in a region called the area postrema, to reduce food intake.4PubMed. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss
Two independent clinical trials confirmed that metformin raises circulating GDF15 in humans, and animal studies have shown that knocking out GDF15 or blocking its receptor completely eliminates metformin’s ability to reduce food intake and body weight.5Nature. GDF15 mediates the effects of metformin on body weight and energy balance Further work identified the kidney as a key source of the GDF15 that metformin stimulates, with kidney-specific knockdown of GDF15 erasing the drug’s appetite-suppressing effects in rats.6Cell Metabolism. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight
What makes this clinically interesting is that metformin’s blood-sugar-lowering ability remains intact even without GDF15. The appetite suppression and the glucose control operate through separate pathways. So if you are on metformin and you find your appetite has dropped, that is a real pharmacological effect, not just nausea from the pill, although metformin-related nausea is common early on and can also reduce eating.
Drugs That Act on Serotonin
Serotonin, a brain chemical best known for its role in mood, also has a direct hand in satiety. One serotonin receptor in particular, the 5-HT2C receptor, helps regulate how full you feel and how much you eat. Lorcaserin (brand name Belviq) was designed to selectively activate this receptor, and it proved effective at curbing appetite in clinical trials.7PubMed Central. Mechanisms of Action of Cassiae Semen for Weight Management: A Computational Molecular Docking Study of Serotonin Receptor 5-HT2C However, the FDA withdrew lorcaserin from the U.S. market in 2020 after a safety trial showed an increased risk of cancer, illustrating a recurring theme with appetite drugs: finding one that works without causing unacceptable harm is genuinely difficult.
Newer research has drilled deeper into how 5-HT2C receptors suppress hunger. Studies in mice have shown that activating these receptors inhibits specific appetite-driving neurons in the hypothalamus, and deleting the receptor from those neurons blunted the appetite-suppressing effect.8PubMed. Serotonin 2C receptors inhibit hypothalamic CRH neurons to suppress appetite This kind of mechanistic detail matters because it may eventually allow drug designers to target the appetite circuit more precisely without the side effects that doomed lorcaserin.
Some older antidepressants, particularly SSRIs like fluoxetine, also reduce appetite in some people during the first months of treatment, likely through overlapping serotonin pathways. The effect tends to fade over time, and certain other antidepressants, like mirtazapine, famously do the opposite and increase appetite substantially.
Topiramate
Topiramate was originally developed as an antiseizure medication, but weight loss kept showing up as a prominent side effect in epilepsy patients. Multiple clinical studies have confirmed that topiramate reduces calorie intake, decreases fat accumulation, and lowers blood lipids like triglycerides and cholesterol. Part of its effect appears to involve dampening the brain’s reward response to food, making eating feel less pleasurable.9PubMed Central. Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review The weight loss effect holds across different doses and is sustained over time, which is relatively unusual for appetite-affecting drugs.
Topiramate is rarely prescribed solely for weight loss on its own because it can cause cognitive side effects, sometimes described as “brain fog” or difficulty finding words. Instead, it is most commonly used for appetite reduction as part of the combination pill phentermine/topiramate (Qsymia), where lower doses of each drug can be used together.
The Bupropion-Naltrexone Combination
Bupropion, an antidepressant that also helps with smoking cessation, and naltrexone, an opioid receptor blocker used in addiction treatment, individually have modest effects on appetite. Combined, they appear to work synergistically. The rationale behind the pairing is that obesity involves both altered hypothalamic hunger signaling and changes in the brain’s reward circuitry that drive food cravings. Bupropion activates appetite-suppressing neurons in the hypothalamus, but the body has a built-in feedback loop that limits this effect. Naltrexone blocks that feedback loop, allowing bupropion’s appetite-reducing signal to persist.10ScienceDirect. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss
This combination (sold as Contrave) is FDA-approved for chronic weight management. It is a useful example of how drugs that work on different pieces of the appetite puzzle can be combined for a stronger effect than either achieves alone.
Opioid Antagonists and the Pleasure of Eating
Naltrexone’s contribution to appetite suppression involves a mechanism that is worth understanding on its own. The brain’s endogenous opioid system, the same system that responds to drugs like morphine, plays a big role in how much pleasure you get from eating. When you bite into something rich or sweet, opioid receptors, particularly mu-opioid receptors, fire up and reinforce the desire to keep eating. Blocking those receptors with an opioid antagonist like naltrexone reduces the hedonic pleasure of palatable food, making it easier to stop eating or to choose less calorie-dense options.11International Journal of Neuropsychopharmacology. From taste hedonics to motivational drive: central µ-opioid receptors and binge-eating behaviour
Animal studies have shown that mice lacking mu-opioid receptors display reduced binge eating on high-fat diets and show less reward-seeking behavior around palatable food.12PubMed. The involvement of the endogenous opioid system in binge eating, food devaluation and food reward in mice This is a distinctly different kind of appetite suppression from, say, a stimulant that just makes you forget to eat. Opioid antagonists specifically target the “I can’t stop eating this because it tastes so good” experience, which is why researchers see them as promising for binge-eating disorder in addition to general obesity.
Nicotine
Smokers have long known that cigarettes blunt hunger, and weight gain after quitting is one of the most common barriers to staying smoke-free. The mechanism has been traced to nicotine’s effect on a specific set of neurons in the hypothalamus. Nicotine activates a type of nicotinic receptor (the α3β4 subtype) on appetite-suppressing POMC neurons, which in turn activate downstream melanocortin receptors that reduce food intake.13PubMed Central. Nicotine decreases food intake through activation of POMC neurons
This is the same melanocortin pathway that several obesity drugs target, which makes nicotine’s appetite effect a genuine pharmacological one rather than just a behavioral distraction. Of course, this does not make smoking a reasonable weight-management strategy. The cardiovascular and cancer risks far outweigh any metabolic benefit. But the finding has helped researchers understand how to design drugs that engage the melanocortin system without requiring nicotine itself.
Amylin Analogues
Amylin is a hormone released by the pancreas alongside insulin after a meal. Its synthetic version, pramlintide (Symlin), is prescribed for diabetes but also suppresses appetite. Amylin slows gastric emptying and sends a satiety signal to the brainstem by binding the area postrema, a region that also mediates nausea, which then relays the signal to other brain areas involved in appetite control.14JCEM Case Reports. Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes Research on combining amylin analogues with GLP-1 drugs is ongoing, based on the idea that engaging two separate appetite-suppressing pathways at once could produce greater effects.
Chemotherapy and Interferon Therapy
Not all drug-induced appetite loss is welcome. Chemotherapy is notorious for destroying patients’ desire to eat. The mechanisms are partly peripheral: chemotherapy drugs can alter taste perception (about 39% of chemotherapy patients experience this), cause mouth sores, trigger nausea and vomiting, and produce abdominal cramping.15PubMed Central. Pathophysiology of anorexia in the cancer cachexia syndrome But chemotherapy also has central effects on brain appetite circuits, and cancer itself produces inflammatory signals that suppress hunger. The resulting weight loss, called cancer cachexia, is a serious medical problem that worsens outcomes and quality of life.
Interferon therapy, used to treat certain cancers and viral infections like hepatitis C, also causes significant appetite loss. Research in mice has shown that type I interferons drive up somatostatin, a hormone that in turn suppresses ghrelin, the body’s primary hunger hormone. The result is rapid weight loss and reduced food intake.16PubMed. Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice Other proposed mechanisms include interferon-induced production of inflammatory molecules like TNF, and direct damage to mitochondria, the cell’s energy-producing machinery.17PubMed. The effects and underlying mechanism of interferon therapy on body weight and body composition
Endocannabinoid Blockers
The endocannabinoid system, the same network that gives cannabis users “the munchies,” is a natural appetite booster. Drugs that block the CB1 cannabinoid receptor powerfully suppress food intake in animal models and were briefly available for human obesity treatment. Rimonabant, the most prominent CB1 inverse agonist, reached the European market but was pulled after reports of serious psychiatric side effects including depression and suicidal thinking.18PubMed Central. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions
Research continues on compounds that interact with CB1 receptors in more nuanced ways. Studies have explored whether neutral antagonists, which block the receptor without pushing it in the opposite direction the way inverse agonists do, can suppress appetite with fewer psychiatric risks. Animal research has shown that appetite suppression by these compounds occurs in two phases: an early phase tied to the drug’s direct receptor activity and a later phase that preferentially reduces intake of high-fat and high-carbohydrate foods.19PubMed. Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities No CB1 blocker is currently approved for human use, but the target remains active in drug development.
Thyroid Hormones
Thyroid hormones have a complicated relationship with appetite. Hyperthyroidism, where the thyroid is overactive, classically increases both metabolic rate and appetite, yet patients often lose weight because the metabolic increase outstrips the rise in eating. What has become clearer more recently is that thyroid hormones also act directly in the brain to regulate appetite signals, not just through their well-known effects on metabolism.20PubMed Central. The central effects of thyroid hormones on appetite For people taking thyroid replacement medications like levothyroxine, being slightly over-replaced can tip the balance toward reduced appetite and unintended weight loss, which is one reason regular blood monitoring matters.
Which Drug Classes Show Up Most in Adverse Reaction Databases
A large analysis of the Japanese adverse drug event database found “decreased appetite” reported as a side effect across 25 different therapeutic drug categories. The most frequently flagged groups were hormone preparations (including anti-hormone drugs), antiviral agents, and antiepileptic drugs.21PubMed Central. Analysis of drug-induced adverse reactions affecting appetite and taste using the Japanese Adverse Drug Event Report Database Antiviral drugs also dominated reports of taste disturbances, which often go hand-in-hand with appetite loss because food that tastes wrong or tastes like nothing holds little appeal.
This database perspective is a useful corrective to the assumption that appetite loss is mainly about weight-loss drugs and stimulants. In reality, many medications you would never associate with dieting, from antiviral regimens to hormone therapies for prostate or breast cancer, reliably suppress appetite as an unintended effect.
When Multiple Drugs Stack Up
Older adults are especially vulnerable to drug-induced appetite loss because they tend to take more medications and because aging itself already reduces appetite through declining smell and taste, slower gastric emptying, and weakened hunger signals from the gut and brain. A systematic review of studies in older people found a consistent statistical link between polypharmacy, generally defined as taking five or more medications, and the risk of becoming malnourished.22ScienceDirect. The association between polypharmacy and malnutrition(risk) in older people: A systematic review The association held regardless of which measurement tools researchers used to assess nutritional status.
The problem is rarely one single drug causing a dramatic appetite crash. Instead, several medications each chip away at hunger by different routes: one alters taste, another causes mild nausea, a third slows gastric motility. Individually the effects might be tolerable, but stacked together they can make eating feel like a chore. If you are caring for an older person who has gradually lost interest in food, a medication review is one of the most practical interventions available. Sometimes removing or substituting one drug can restore enough appetite to make a real nutritional difference.
Drugs That Do the Opposite
For the sake of completeness, it is worth knowing that some medications are prescribed specifically to increase appetite. These orexigenic drugs, including megestrol acetate, dronabinol, and mirtazapine, are used in patients with cancer cachexia, HIV-related wasting, or severe geriatric malnutrition. They have been shown to improve appetite and produce weight gain, possibly by suppressing inflammatory signals that drive appetite loss.23PubMed Central. Guidelines for the use of orexigenic drugs in long-term care The fact that appetite-stimulating drugs exist underscores how pharmacologically malleable hunger is: the same brain circuits that can be dialed down by stimulants or GLP-1 drugs can be turned back up with different compounds when the clinical need runs in the other direction.